1003 related articles for article (PubMed ID: 17402211)
1. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
Macavei I; Galatâr N
Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
[TBL] [Abstract][Full Text] [Related]
3. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
Scott LM; Tong W; Levine RL; Scott MA; Beer PA; Stratton MR; Futreal PA; Erber WN; McMullin MF; Harrison CN; Warren AJ; Gilliland DG; Lodish HF; Green AR
N Engl J Med; 2007 Feb; 356(5):459-68. PubMed ID: 17267906
[TBL] [Abstract][Full Text] [Related]
4. Interferon in the treatment of myeloproliferative diseases.
Silver RT
Semin Hematol; 1990 Jul; 27(3 Suppl 4):6-14. PubMed ID: 2115694
[TBL] [Abstract][Full Text] [Related]
5. [Use of interferon in the treatment of chronic myeloproliferative disorders].
Robak T
Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870
[TBL] [Abstract][Full Text] [Related]
6. [Familial myeloproliferative syndromes. Study of 6 families and review of literature].
Kaufman S; Brière J; Bernard J
Nouv Rev Fr Hematol (1978); 1978 Apr; 20(1):1-15. PubMed ID: 353725
[TBL] [Abstract][Full Text] [Related]
7. Stem cell origin of human myeloid blood cell neoplasms.
Fialkow PJ
Verh Dtsch Ges Pathol; 1990; 74():43-7. PubMed ID: 1708632
[TBL] [Abstract][Full Text] [Related]
8. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.
Nangalia J; Massie CE; Baxter EJ; Nice FL; Gundem G; Wedge DC; Avezov E; Li J; Kollmann K; Kent DG; Aziz A; Godfrey AL; Hinton J; Martincorena I; Van Loo P; Jones AV; Guglielmelli P; Tarpey P; Harding HP; Fitzpatrick JD; Goudie CT; Ortmann CA; Loughran SJ; Raine K; Jones DR; Butler AP; Teague JW; O'Meara S; McLaren S; Bianchi M; Silber Y; Dimitropoulou D; Bloxham D; Mudie L; Maddison M; Robinson B; Keohane C; Maclean C; Hill K; Orchard K; Tauro S; Du MQ; Greaves M; Bowen D; Huntly BJP; Harrison CN; Cross NCP; Ron D; Vannucchi AM; Papaemmanuil E; Campbell PJ; Green AR
N Engl J Med; 2013 Dec; 369(25):2391-2405. PubMed ID: 24325359
[TBL] [Abstract][Full Text] [Related]
9. Introduction and overview of interferon alfa in myeloproliferative and hemangiomatous diseases.
Appelbaum FR
Semin Hematol; 1990 Jul; 27(3 Suppl 4):1-5. PubMed ID: 2197729
[TBL] [Abstract][Full Text] [Related]
10. Myeloproliferative neoplasms.
Publicover A; Medd P
Clin Med (Lond); 2013 Apr; 13(2):188-92. PubMed ID: 23681871
[TBL] [Abstract][Full Text] [Related]
11. Increased fibroblast colony stimulating activity (F-CSA) in serum of myeloproliferative disorders.
Han ZC; Briere J; Parent D; Abgrall JF; Sensebe L
J Biol Regul Homeost Agents; 1988; 2(3):119-24. PubMed ID: 3267102
[TBL] [Abstract][Full Text] [Related]
12. Antigenic phenotype of myelomonocytic progenitors (CFU-GM) in chronic myeloproliferative disorders.
Ferrero D; Tarella C; Pregno P; Pileri A; Gallo E
Cancer Res; 1986 Feb; 46(2):975-80. PubMed ID: 3455679
[TBL] [Abstract][Full Text] [Related]
13. [Clinico-hematological characteristics of acute transformation of chronic myeloproliferative syndromes].
Hernández JM; San Miguel JF; González M; Moraleda JM; Moro MJ; Hernández J; Cuesta B; López Borrasca A
Med Clin (Barc); 1991 Sep; 97(10):369-72. PubMed ID: 1745085
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation.
Hermouet S; Bigot-Corbel E; Gardie B
Mediators Inflamm; 2015; 2015():145293. PubMed ID: 26538820
[TBL] [Abstract][Full Text] [Related]
15. Leukaemia cytogenetics.
Woodliff HJ
Med J Aust; 1975 Apr; 1(16):495-9. PubMed ID: 124393
[No Abstract] [Full Text] [Related]
16. [The significance of the PAS-reaction in myeloproliferative diseases].
Krug K; Stenzel L
Folia Haematol Int Mag Klin Morphol Blutforsch; 1969; 91(2):307-13. PubMed ID: 4184596
[No Abstract] [Full Text] [Related]
17. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.
Jones AV; Chase A; Silver RT; Oscier D; Zoi K; Wang YL; Cario H; Pahl HL; Collins A; Reiter A; Grand F; Cross NC
Nat Genet; 2009 Apr; 41(4):446-9. PubMed ID: 19287382
[TBL] [Abstract][Full Text] [Related]
18. [Myeloproliferative syndrome].
Nowotny P; Preussfner S; Konrad H; Engelmann C; Günther I
Z Gesamte Inn Med; 1976 Apr; 31(8):250-4. PubMed ID: 986731
[TBL] [Abstract][Full Text] [Related]
19. [Diagnosis of chronic myeloproliferative diseases based on bone marrow biopsy].
Matolcsy A; Kónya T; Wéber E
Orv Hetil; 1992 Jun; 133(26):1617-20, 1625-6. PubMed ID: 1614699
[TBL] [Abstract][Full Text] [Related]
20. In vitro culture techniques defining biological abnormalities in the myelodysplastic syndromes and myeloproliferative disorders.
Greenberg PL
Clin Haematol; 1986 Nov; 15(4):973-93. PubMed ID: 3552351
[No Abstract] [Full Text] [Related]
[Next] [New Search]
